Ilypsa Overview

Ilypsa, Inc. is a biopharmaceutical company pioneering the use of a proprietary high throughput discovery and development platform created and validated at Symyx Technologies. Ilypsa is currently conducting drug discovery and development programs across several therapeutic areas using its automated and integrated suite of technologies and informatics in chemistry and biology. The product...More»

Ilypsa, Inc. is a biopharmaceutical company pioneering the use of a proprietary high throughput discovery and development platform created and validated at Symyx Technologies. Ilypsa is currently conducting drug discovery and development programs across several therapeutic areas using its automated and integrated suite of technologies and informatics in chemistry and biology. The product pipeline mainly focuses on metabolic diseases and reflects candidates with significant market opportunities and short development timelines. The Ilypsa approach combines a unique discovery and development engine with carefully chosen drug targets that enable novel drug candidates in areas of substantial medical need with very attractive timelines and risk profiles.

Amgen acquired Ilypsa in 2007.«Less